帕利珠单抗 (Chinese Wikipedia)
Analysis of information sources in references of the Wikipedia article "帕利珠单抗" in Chinese language version.
refsWebsite
Global rank
Chinese rank
1st place
1st place
11th place
332nd place
3,823rd place
3,456th place
5,225th place
4,888th place
6th place
4th place
3rd place
8th place
102nd place
492nd place
archive.org (Global: 6th place; Chinese: 4th place)
- Levinson W. Medical Microbiology and Immunology
8th. Lange. 2004: 430. ISBN 9780071431996.
books.google.com (Global: 3rd place; Chinese: 8th place)
- Long SS, Pickering LK, Prober CG. Principles and Practice of Pediatric Infectious Disease. Elsevier Health Sciences. 2012: 1502 [2023-12-15]. ISBN 978-1437727029. （原始内容存档于2023-01-10） （英语）.
cdc.gov (Global: 218th place; Chinese: 198th place)
- CDC. Trends and Surveillance for RSV in the US.. Centers for Disease Control and Prevention. 2020-12-18 [2021-08-10]. （原始内容存档于2023-06-28） （美国英语）.
clinicaltrials.gov (Global: 5,225th place; Chinese: 4,888th place)
- Prospective Study for the Use of Palivizumab (Synagis®) in High-risk Children in Germany. ClinicalTrials.gov. 2021 [2023-12-15]. （原始内容存档于2023-03-11）.
doi.org (Global: 2nd place; Chinese: 23rd place)
- Borchers AT, Chang C, Gershwin ME, Gershwin LJ. Respiratory syncytial virus--a comprehensive review. Clinical Reviews in Allergy & Immunology. December 2013, 45 (3): 331–379. PMC 7090643
. PMID 23575961. doi:10.1007/s12016-013-8368-9. - Santos da Silva GN, Monti Atik D, Antunes Fernandes JL, de Freitas do Nascimento D, Fazolo T, Duarte de Souza AP, Baggio Gnoatto SC. Synthesis of three triterpene series and their activity against respiratory syncytial virus. Archiv der Pharmazie. July 2018, 351 (8): e1800108. PMID 29999539. S2CID 51621538. doi:10.1002/ardp.201800108. hdl:10923/21468 .
- Brady MT, Byington CL, Davies HD, Edwards KM, Jackson MA, Maldonado YA, et al. Updated guidance for palivizumab prophylaxis among infants and young children at increased risk of hospitalization for respiratory syncytial virus infection. Pediatrics. August 2014, 134 (2): 415–420. PMID 25070315. doi:10.1542/peds.2014-1665 . 已忽略未知参数
|collaboration=(帮助) - Andabaka T, Nickerson JW, Rojas-Reyes MX, Rueda JD, Bacic Vrca V, Barsic B. Monoclonal antibody for reducing the risk of respiratory syncytial virus infection in children. The Cochrane Database of Systematic Reviews. April 2013, (4): CD006602. PMID 23633336. doi:10.1002/14651858.cd006602.pub4.
- Garegnani L, Styrmisdóttir L, Roson Rodriguez P, Escobar Liquitay CM, Esteban I, Franco JV. Cochrane Acute Respiratory Infections Group , 编. Palivizumab for preventing severe respiratory syncytial virus (RSV) infection in children. The Cochrane Database of Systematic Reviews. November 2021, 2021 (11): CD013757. PMC 8594174 . PMID 34783356. doi:10.1002/14651858.CD013757.pub2.
- Sanders SL, Agwan S, Hassan M, Bont LJ, Venekamp RP. Immunoglobulin treatment for hospitalised infants and young children with respiratory syncytial virus infection. The Cochrane Database of Systematic Reviews. October 2023, 2023 (10): CD009417. PMC 10591280 . PMID 37870128. doi:10.1002/14651858.CD009417.pub3. 已忽略未知参数
|pmc-embargo-date=(帮助) - Hu J, Robinson JL. Treatment of respiratory syncytial virus with palivizumab: a systematic review. World Journal of Pediatrics. November 2010, 6 (4): 296–300. PMID 21080142. S2CID 22504710. doi:10.1007/s12519-010-0230-z.
- Ferla S, Manganaro R, Benato S, Paulissen J, Neyts J, Jochmans D, et al. Rational modifications, synthesis and biological evaluation of new potential antivirals for RSV designed to target the M2-1 protein. Bioorganic & Medicinal Chemistry. April 2020, 28 (8): 115401. PMID 32143992. S2CID 212622222. doi:10.1016/j.bmc.2020.115401.
europa.eu (Global: 68th place; Chinese: 209th place)
ema.europa.eu
- Synagis EPAR. European Medicines Agency (EMA). 17 September 2018 [20 August 2020]. （原始内容存档于2020-08-15）. Text was copied from this source which is © European Medicines Agency. Reproduction is authorized provided the source is acknowledged.
fda.gov (Global: 447th place; Chinese: 581st place)
accessdata.fda.gov
- Drugs@FDA: FDA-Approved Drugs. www.accessdata.fda.gov. [28 July 2021]. （原始内容存档于2021-07-28）.
handle.net (Global: 102nd place; Chinese: 492nd place)
hdl.handle.net
- Santos da Silva GN, Monti Atik D, Antunes Fernandes JL, de Freitas do Nascimento D, Fazolo T, Duarte de Souza AP, Baggio Gnoatto SC. Synthesis of three triterpene series and their activity against respiratory syncytial virus. Archiv der Pharmazie. July 2018, 351 (8): e1800108. PMID 29999539. S2CID 51621538. doi:10.1002/ardp.201800108. hdl:10923/21468 .
medicines.org.uk (Global: 3,823rd place; Chinese: 3,456th place)
- Synagis 100 mg/ml solution for injection - Summary of Product Characteristics (SmPC). (emc). 12 August 2020 [20 August 2020]. （原始内容存档于2021-03-02）.
nih.gov (Global: 4th place; Chinese: 5th place)
ncbi.nlm.nih.gov
- Borchers AT, Chang C, Gershwin ME, Gershwin LJ. Respiratory syncytial virus--a comprehensive review. Clinical Reviews in Allergy & Immunology. December 2013, 45 (3): 331–379. PMC 7090643 . PMID 23575961. doi:10.1007/s12016-013-8368-9.
- Santos da Silva GN, Monti Atik D, Antunes Fernandes JL, de Freitas do Nascimento D, Fazolo T, Duarte de Souza AP, Baggio Gnoatto SC. Synthesis of three triterpene series and their activity against respiratory syncytial virus. Archiv der Pharmazie. July 2018, 351 (8): e1800108. PMID 29999539. S2CID 51621538. doi:10.1002/ardp.201800108. hdl:10923/21468 .
- Brady MT, Byington CL, Davies HD, Edwards KM, Jackson MA, Maldonado YA, et al. Updated guidance for palivizumab prophylaxis among infants and young children at increased risk of hospitalization for respiratory syncytial virus infection. Pediatrics. August 2014, 134 (2): 415–420. PMID 25070315. doi:10.1542/peds.2014-1665 . 已忽略未知参数
|collaboration=(帮助) - Andabaka T, Nickerson JW, Rojas-Reyes MX, Rueda JD, Bacic Vrca V, Barsic B. Monoclonal antibody for reducing the risk of respiratory syncytial virus infection in children. The Cochrane Database of Systematic Reviews. April 2013, (4): CD006602. PMID 23633336. doi:10.1002/14651858.cd006602.pub4.
- Garegnani L, Styrmisdóttir L, Roson Rodriguez P, Escobar Liquitay CM, Esteban I, Franco JV. Cochrane Acute Respiratory Infections Group , 编. Palivizumab for preventing severe respiratory syncytial virus (RSV) infection in children. The Cochrane Database of Systematic Reviews. November 2021, 2021 (11): CD013757. PMC 8594174 . PMID 34783356. doi:10.1002/14651858.CD013757.pub2.
- Sanders SL, Agwan S, Hassan M, Bont LJ, Venekamp RP. Immunoglobulin treatment for hospitalised infants and young children with respiratory syncytial virus infection. The Cochrane Database of Systematic Reviews. October 2023, 2023 (10): CD009417. PMC 10591280 . PMID 37870128. doi:10.1002/14651858.CD009417.pub3. 已忽略未知参数
|pmc-embargo-date=(帮助) - Hu J, Robinson JL. Treatment of respiratory syncytial virus with palivizumab: a systematic review. World Journal of Pediatrics. November 2010, 6 (4): 296–300. PMID 21080142. S2CID 22504710. doi:10.1007/s12519-010-0230-z.
- Ferla S, Manganaro R, Benato S, Paulissen J, Neyts J, Jochmans D, et al. Rational modifications, synthesis and biological evaluation of new potential antivirals for RSV designed to target the M2-1 protein. Bioorganic & Medicinal Chemistry. April 2020, 28 (8): 115401. PMID 32143992. S2CID 212622222. doi:10.1016/j.bmc.2020.115401.
dailymed.nlm.nih.gov
- Synagis- palivizumab injection, solution. DailyMed. 12 May 2017 [20 August 2020]. （原始内容存档于2020-08-07）.
semanticscholar.org (Global: 11th place; Chinese: 332nd place)
api.semanticscholar.org
- Santos da Silva GN, Monti Atik D, Antunes Fernandes JL, de Freitas do Nascimento D, Fazolo T, Duarte de Souza AP, Baggio Gnoatto SC. Synthesis of three triterpene series and their activity against respiratory syncytial virus. Archiv der Pharmazie. July 2018, 351 (8): e1800108. PMID 29999539. S2CID 51621538. doi:10.1002/ardp.201800108. hdl:10923/21468 .
- Hu J, Robinson JL. Treatment of respiratory syncytial virus with palivizumab: a systematic review. World Journal of Pediatrics. November 2010, 6 (4): 296–300. PMID 21080142. S2CID 22504710. doi:10.1007/s12519-010-0230-z.
- Ferla S, Manganaro R, Benato S, Paulissen J, Neyts J, Jochmans D, et al. Rational modifications, synthesis and biological evaluation of new potential antivirals for RSV designed to target the M2-1 protein. Bioorganic & Medicinal Chemistry. April 2020, 28 (8): 115401. PMID 32143992. S2CID 212622222. doi:10.1016/j.bmc.2020.115401.
web.archive.org (Global: 1st place; Chinese: 1st place)
- Synagis 100 mg/ml solution for injection - Summary of Product Characteristics (SmPC). (emc). 12 August 2020 [20 August 2020]. （原始内容存档于2021-03-02）.
- Synagis- palivizumab injection, solution. DailyMed. 12 May 2017 [20 August 2020]. （原始内容存档于2020-08-07）.
- Synagis EPAR. European Medicines Agency (EMA). 17 September 2018 [20 August 2020]. （原始内容存档于2020-08-15）. Text was copied from this source which is © European Medicines Agency. Reproduction is authorized provided the source is acknowledged.
- Prospective Study for the Use of Palivizumab (Synagis®) in High-risk Children in Germany. ClinicalTrials.gov. 2021 [2023-12-15]. （原始内容存档于2023-03-11）.
- CDC. Trends and Surveillance for RSV in the US.. Centers for Disease Control and Prevention. 2020-12-18 [2021-08-10]. （原始内容存档于2023-06-28） （美国英语）.
- Long SS, Pickering LK, Prober CG. Principles and Practice of Pediatric Infectious Disease. Elsevier Health Sciences. 2012: 1502 [2023-12-15]. ISBN 978-1437727029. （原始内容存档于2023-01-10） （英语）.
- Drugs@FDA: FDA-Approved Drugs. www.accessdata.fda.gov. [28 July 2021]. （原始内容存档于2021-07-28）.